## Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

## If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

# Cell Survival in Rat Rhabdomyosarcoma Tumors Irradiated in Vivo with Extended-Peak Silicon Ions

T. S. Tenforde, S. M. J. Afzal, S. S. Parr, J. Howard, J. T. Lyman and S. B. Curtis
Vol. 92, No. 1 (Oct., 1982), pp. 208-216
DOI: 10.2307/3575856
Stable URL: http://www.jstor.org/stable/3575856
Page Count: 9
Preview not available

## Abstract

Cell survival curves were measured by the in vivo to in vitro assay procedure for rat rhabdomyosarcoma tumors irradiated in the distal 4-cm extended-peak region of a 670-MeV/u silicon-ion beam. RBE values determined relative to 225-kVp X rays for the killing of oxygenated tumor cells were 2.1 and 2.2 at the 1 and 10% survival levels, respectively. These RBE values are greater than those obtained previously for extended-peak carbon ions (1.7-1.8), but less than those obtained for extended-peak neon ions (2.5-2.7). This observation indicates that the RBE obtained in the distal-peak region of the 670 MeV/u silicon-ion beam lies beyond the maximum in the RBE versus ${\rm LET}_{\infty}$ curve for the killing of oxygenated tumor cells. The RBE value for the killing of hypoxic tumor cells in this beam was 3.6 at both the 1 and 10% survival levels. This RBE value exceeds the previously measured values for both extended-peak carbon ions (2.0) and extended-peak neon ions (3.1-3.3). OER values measured at the 1 and 10% survival levels for silicon ions were 1.2 and 1.3, respectively, compared to 1.7 for neon ions and 1.9 for carbon ions. The significant reduction in oxygen effect for accelerated silicon ions relative to the lighter elements suggests that this beam may be efficacious for the treatment of tumors whose probability of cure is limited by a large fraction of hypoxic cells.

• 208
• 209
• 210
• 211
• 212
• 213
• 214
• 215
• 216